Increased functional connectivity between nucleus basalis of Meynert and amygdala in cognitively intact elderly along the Alzheimer's continuum.
AT(N) classification system
Alzheimer’s disease continuum
Basal forebrain cholinergic system
Cognitively intact elderly
Functional connectivity
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
06
2022
revised:
16
10
2022
accepted:
31
10
2022
pubmed:
2
12
2022
medline:
15
12
2022
entrez:
1
12
2022
Statut:
ppublish
Résumé
A growing body of research reported the degeneration of the basal forebrain (BF) cholinergic system in the early course of Alzheimer's disease (AD). However, functional changes of the BF in asymptomatic individuals along the Alzheimer's continuum remain unclear. A total of 229 cognitively intact participants were included from the Alzheimer's Disease Neuroimaging Initiative dataset and further divided into four groups based on the "A/T" profile using amyloid and tau positron emission tomography (PET). All A-T+ subjects were excluded. One hundred and seventy-three subjects along the Alzheimer's continuum (A-T-, A+ T-, A+ T+) were used for further study. The seed-based functional connectivity (FC) maps of the BF subregions (Ch1-3 and Ch4 [nucleus basalis of Meynert, NBM]) with whole-brain voxels were constructed. Analyses of covariance to detect the between-group differences and to further investigated the relations between FC values and AD biomarkers or cognition. We found increased FC between right Ch4 and bilateral amygdala among three groups, and the FC value could well distinguish between the A-T- group and the Alzheimer's continuum groups. Furthermore, increased FC between the Ch4 and amygdala was associated with higher pathological burden reflected by amyloid and tau PET in the entire population as well as better logistic memory function in A + T+ group. Our study demonstrated the NBM functional connectivity increased in cognitively normal elderly along the Alzheimer's continuum, which indicated a potential compensatory mechanism to counteract pathological changes in AD and maintain intact cognitive function.
Sections du résumé
BACKGROUND
BACKGROUND
A growing body of research reported the degeneration of the basal forebrain (BF) cholinergic system in the early course of Alzheimer's disease (AD). However, functional changes of the BF in asymptomatic individuals along the Alzheimer's continuum remain unclear.
METHODS
METHODS
A total of 229 cognitively intact participants were included from the Alzheimer's Disease Neuroimaging Initiative dataset and further divided into four groups based on the "A/T" profile using amyloid and tau positron emission tomography (PET). All A-T+ subjects were excluded. One hundred and seventy-three subjects along the Alzheimer's continuum (A-T-, A+ T-, A+ T+) were used for further study. The seed-based functional connectivity (FC) maps of the BF subregions (Ch1-3 and Ch4 [nucleus basalis of Meynert, NBM]) with whole-brain voxels were constructed. Analyses of covariance to detect the between-group differences and to further investigated the relations between FC values and AD biomarkers or cognition.
RESULTS
RESULTS
We found increased FC between right Ch4 and bilateral amygdala among three groups, and the FC value could well distinguish between the A-T- group and the Alzheimer's continuum groups. Furthermore, increased FC between the Ch4 and amygdala was associated with higher pathological burden reflected by amyloid and tau PET in the entire population as well as better logistic memory function in A + T+ group.
CONCLUSION
CONCLUSIONS
Our study demonstrated the NBM functional connectivity increased in cognitively normal elderly along the Alzheimer's continuum, which indicated a potential compensatory mechanism to counteract pathological changes in AD and maintain intact cognitive function.
Identifiants
pubmed: 36451361
pii: S2213-1582(22)00321-7
doi: 10.1016/j.nicl.2022.103256
pmc: PMC9668640
pii:
doi:
Substances chimiques
Amyloid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103256Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Biol Psychiatry. 2012 May 1;71(9):805-13
pubmed: 21816388
Cereb Cortex. 2010 Jul;20(7):1685-95
pubmed: 19889714
Alzheimers Dement. 2014 Oct;10(5 Suppl):S344-53
pubmed: 24418052
Brain. 2022 Jun 3;145(5):1773-1784
pubmed: 34605858
JAMA Neurol. 2022 Feb 1;79(2):149-158
pubmed: 34928318
Brain. 2005 Nov;128(Pt 11):2626-44
pubmed: 16014654
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
Front Aging Neurosci. 2021 Jun 25;13:671351
pubmed: 34248603
Ann Neurol. 2016 Aug;80(2):247-58
pubmed: 27323247
Neurobiol Aging. 2013 Apr;34(4):1210-20
pubmed: 23158764
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Neurobiol Aging. 2014 Mar;35(3):482-91
pubmed: 24176625
Arch Gen Psychiatry. 2006 Jan;63(1):57-62
pubmed: 16389197
Radiology. 2019 Jan;290(1):167-176
pubmed: 30351255
J Magn Reson Imaging. 2020 Feb;51(2):505-513
pubmed: 31145515
J Comp Neurol. 1983 Feb 20;214(2):170-97
pubmed: 6841683
Brain. 2020 Mar 1;143(3):993-1009
pubmed: 32203580
Neuroinformatics. 2016 Jul;14(3):339-51
pubmed: 27075850
Neurology. 2022 Feb 15;98(7):e700-e710
pubmed: 34906980
J Comp Neurol. 1988 Sep 8;275(2):216-40
pubmed: 3220975
Alzheimers Res Ther. 2021 May 10;13(1):99
pubmed: 33971965
Ann Neurol. 2012 Oct;72(4):578-86
pubmed: 23109153
Cereb Cortex. 2020 Apr 14;30(4):2083-2098
pubmed: 31799623
Ann Neurol. 2004 Jun;55(6):815-28
pubmed: 15174015
Brain. 2016 May;139(Pt 5):1539-50
pubmed: 26936940
Brain. 2018 Jul 1;141(7):1917-1933
pubmed: 29850777
JAMA Neurol. 2020 Feb 1;77(2):225-233
pubmed: 31657834
Curr Top Behav Neurosci. 2018;37:253-273
pubmed: 28213811
Neurochem Int. 2008 Nov;53(5):103-11
pubmed: 18602955
Brain Connect. 2014 Dec;4(10):780-90
pubmed: 25083734
Neurobiol Aging. 2012 Apr;33(4):825.e25-36
pubmed: 21782287
Curr Biol. 2007 Oct 23;17(20):R868-74
pubmed: 17956742
Rev Neurosci. 2020 May 26;31(4):391-413
pubmed: 32017704
Neuroimage. 2020 May 1;211:116607
pubmed: 32035186
Neuroimage. 2008 Sep 1;42(3):1127-41
pubmed: 18585468
Lancet. 2016 Jul 30;388(10043):505-17
pubmed: 26921134
Nat Rev Neurosci. 2006 Jan;7(1):54-64
pubmed: 16371950
Hum Brain Mapp. 2011 Sep;32(9):1349-62
pubmed: 20672311
Neurobiol Aging. 2020 Mar;87:70-77
pubmed: 32008856
J Alzheimers Dis. 2022;86(1):425-440
pubmed: 35068451
Prog Neurobiol. 1997 Aug;52(6):511-35
pubmed: 9316159
Neurology. 2022 Mar 1;98(9):e947-e957
pubmed: 34969939